Stoke Therapeutics (NASDAQ:STOK) Insider Sells $209,539.24 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 6,686 shares of the firm’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total transaction of $209,539.24. Following the transaction, the insider owned 40,798 shares of the company’s stock, valued at approximately $1,278,609.32. This represents a 14.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Barry Ticho also recently made the following trade(s):

• On Tuesday, March 17th, Barry Ticho sold 6,164 shares of Stoke Therapeutics stock. The shares were sold at an average price of $33.01, for a total value of $203,473.64.
• On Thursday, March 19th, Barry Ticho sold 1,461 shares of Stoke Therapeutics stock. The stock was sold at an average price of $29.99, for a total value of $43,815.39.

Stoke Therapeutics Price Performance

Stoke Therapeutics stock opened at $33.51 on Friday. The business has a 50 day simple moving average of $32.61 and a 200 day simple moving average of $30.09. The company has a market capitalization of $1.98 billion, a PE ratio of 50.01 and a beta of 1.07. Stoke Therapeutics, Inc. has a one year low of $5.35 and a one year high of $40.22.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Kestra Advisory Services LLC bought a new stake in Stoke Therapeutics during the 4th quarter worth about $26,000. Harbour Investments Inc. raised its stake in shares of Stoke Therapeutics by 312.9% in the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after acquiring an additional 898 shares during the last quarter. Generali Investments Management Co LLC acquired a new position in shares of Stoke Therapeutics during the third quarter worth approximately $41,000. BNP Paribas Financial Markets lifted its position in shares of Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after purchasing an additional 1,668 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of Stoke Therapeutics by 461.0% during the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after purchasing an additional 3,591 shares during the last quarter.

Key Stories Impacting Stoke Therapeutics

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Canaccord raised its price target sharply to $60 and assigned a Buy, giving STOK a meaningful upside projection versus recent levels — a clear catalyst for buying interest. Canaccord raises STOK price target to $60 (Benzinga)
• Positive Sentiment: Other analysts reiterated/raised Buy views and targets (BTIG reaffirmed Buy with a $39 target; Wedbush pushed its target to $38; Needham published a bullish outlook), adding breadth to the bullish narrative and likely attracting momentum and institutional buyers. BTIG reaffirmation (Benzinga) Wedbush boosts price target to $38 (AmericanBankingNews) Needham bullish outlook (AmericanBankingNews)
• Positive Sentiment: Coverage of Stoke’s STK‑001 program emphasizes potential beyond seizure reduction (aiming to restore developmental loss in Dravet syndrome), supporting longer‑term upside expectations if clinical data meet endpoints. FierceBiotech: Stoke aims to restore developmental loss in Dravet syndrome
• Neutral Sentiment: Analysis pieces reviewed a recent sharp pullback and what triggered it—useful context for traders but not a new company catalyst. Kalkine: What triggered the sudden drop?
• Neutral Sentiment: Technical/volume note — today’s volume is well above average and the stock is trading above both its 50‑ and 200‑day SMAs, indicating higher investor interest; this can amplify moves in either direction.
• Negative Sentiment: Significant insider selling: multiple executives (including the CFO, general counsel and senior insiders such as Barry Ticho) disclosed sizable sales across March 17–19, which can weigh on sentiment and prompt investor caution despite analyst optimism. Representative SEC filings: SEC Form 4 (Jonathan Allan) SEC Form 4 (Barry Ticho)

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Guggenheim started coverage on shares of Stoke Therapeutics in a research report on Thursday, February 5th. They set a “buy” rating and a $60.00 target price for the company. Weiss Ratings restated a “hold (c-)” rating on shares of Stoke Therapeutics in a research report on Monday, December 29th. Wall Street Zen cut shares of Stoke Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Wolfe Research started coverage on shares of Stoke Therapeutics in a report on Monday, February 23rd. They set an “outperform” rating and a $40.00 price objective for the company. Finally, UBS Group set a $50.00 target price on shares of Stoke Therapeutics in a research note on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $41.83.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.